Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD | Zendy

Claus Vogelmeier | Zendy; Bettina Hederer | Zendy; Thomas Glaab | Zendy; Hendrik Schmidt | Zendy; Maureen Ruttenvan Mölken | Zendy; Kai Michael Beeh | Zendy; Klaus F. Rabe | Zendy; Leonardo M. Fabbri | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

Author(s) -

Claus Vogelmeier,

Bettina Hederer,

Thomas Glaab,

Hendrik Schmidt,

Maureen Ruttenvan Mölken,

Kai Michael Beeh,

Klaus F. Rabe,

Leonardo M. Fabbri

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1008378

Subject(s) - salmeterol , medicine , copd , bronchodilator agents , tiotropium bromide , intensive care medicine , bronchodilator , asthma , lung function , lung

Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a β(2)-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the β(2)-agonist salmeterol in preventing exacerbations of COPD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research